Display options
Cite
Nasr AB, Ponnala D, Sagurthi SR, et al. Molecular Docking studies of FKBP12-mTOR inhibitors using binding predictions. Bioinformation. 2015;11(6):307-15doi: 10.6026/97320630011307.
Nasr, A. B., Ponnala, D., Sagurthi, S. R., Kattamuri, R. K., Marri, V. K., Gudala, S., Lakkaraju, C., Bandaru, S., & Nayarisseri, A. (2015). Molecular Docking studies of FKBP12-mTOR inhibitors using binding predictions. Bioinformation, 11(6), 307-15. https://doi.org/10.6026/97320630011307
Nasr, Arash Boroumand, et al. "Molecular Docking studies of FKBP12-mTOR inhibitors using binding predictions." Bioinformation vol. 11,6 (2015): 307-15. doi: https://doi.org/10.6026/97320630011307
Nasr AB, Ponnala D, Sagurthi SR, Kattamuri RK, Marri VK, Gudala S, Lakkaraju C, Bandaru S, Nayarisseri A. Molecular Docking studies of FKBP12-mTOR inhibitors using binding predictions. Bioinformation. 2015 Jun 30;11(6):307-15. doi: 10.6026/97320630011307. eCollection 2015. PMID: 26229292; PMCID: PMC4512006.
Copy Download .nbib Format: NLM
Share it on

Bioinformation. 2015 Jun 30;11(6):307-15. doi: 10.6026/97320630011307. eCollection 2015.

Molecular Docking studies of FKBP12-mTOR inhibitors using binding predictions.

Bioinformation

Arash Boroumand Nasr, Deepika Ponnala, Someshwar Rao Sagurthi, Ramesh Kumar Kattamuri, Vijaya Kumar Marri, Suresh Gudala, Chandana Lakkaraju, Srinivas Bandaru, Anuraj Nayarisseri

Affiliations

  1. Institute of Genetics and Hospital for Genetic Diseases, Osmania University, Hyderabad - 500 016, India.
  2. Department of Genetics, Osmania University, Hyderabad - 500 007, India.
  3. Government General and Chest Hospital, Gandhi Medical College and Osmania Medical College, Hyderabad - 500 038, India.
  4. Institute of Genetics and Hospital for Genetic Diseases, Osmania University, Hyderabad - 500 016, India ; National Institute of Pharmaceutical Education and Research, Hyderabad - 500 037, India.
  5. In silico Research Laboratory, Eminent Biosciences, Indore - 452 010, Madhya Pradesh, India.

PMID: 26229292 PMCID: PMC4512006 DOI: 10.6026/97320630011307

Abstract

UNLABELLED: Mammalian target of rapamycin (mTOR) is a key regulator of cell growth, proliferation and angiogenesis. mTOR signaling is frequently hyper activated in a broad spectrum of human cancers thereby making it a potential drug target. The current drugs available have been successful in inhibiting the mTOR signaling, nevertheless, show low oral bioavailability and suboptimal solubility. Considering the narrow therapeutic window of the available inhibitors, through computational approaches, the present study pursues to identify a compound with optimal oral bioavailability and better solubility properties in addition ensuing high affinity between FKBP12 and FRB domain of mTOR. Current mTOR inhibitors; Everolimus, Temsirolimus Deforolimus and Echinomycin served as parent molecules for similarity search with a threshold of 95%. The query molecules and respective similar molecules were docked at the binding cleft of FKBP12 protein. Aided by MolDock algorithm, high affinity compounds against FKBP12 were retrieved. Patch Dock supervised protein-protein interactions were established between FRB domain of mTOR and ligand (query and similar) bound and free states of FKBP12. All the similar compounds thus retrieved showed better solubility properties and enabled better complex formation of mTOR and FKBP12. In particular Everolimus similar compound PubChem ID: 57284959 showed appreciable drugs like properties bestowed with better solubility higher oral bioavailability. In addition this compound brought about enhanced interaction between FKBP12 and FRB domain of mTOR. In the study, we report Everolimus similar compound PubChem ID: 57284959 to be potential inhibitor for mTOR pathway which can overcome the affinity and solubility concerns of current mTOR drugs.

ABBREVIATIONS: mTOR - Mammalian Target of Rapamycin, FRB domain - FKBP12-rapamycin associated protein, FKBP12 - FK506-binding protein 12, OPLS - Optimized Potentials for Liquid Simulations, Akt - RAC-alpha serine/threonine-protein kinase, PI3K - phosphatidylinositide 3-kinases.

Keywords: FKBP12; FRB domain; Human oral absorption; Protein-protein interactions; Solubility; mTOR; virtual screening

References

  1. Nucleic Acids Res. 2013 Jan;41(Database issue):D824-7 - PubMed
  2. Cancer Metastasis Rev. 2001;20(1-2):69-78 - PubMed
  3. Science. 2001 Nov 2;294(5544):1102-5 - PubMed
  4. J Neuropathol Exp Neurol. 2004 Dec;63(12):1236-42 - PubMed
  5. Curr Top Med Chem. 2015;15(1):50-6 - PubMed
  6. Ann Oncol. 2008 Aug;19(8):1387-92 - PubMed
  7. J Chem Inf Model. 2012 Nov 26;52(11):3099-105 - PubMed
  8. Oncogene. 2004 Apr 19;23(18):3230-47 - PubMed
  9. Cell. 2003 Nov 26;115(5):577-90 - PubMed
  10. Acta Crystallogr D Biol Crystallogr. 1999 Apr;55(Pt 4):736-44 - PubMed
  11. Ann Oncol. 2013 Aug;24(8):2092-7 - PubMed
  12. Cancer Res. 2006 Jun 1;66(11):5618-23 - PubMed
  13. Bioinformation. 2014 Oct 30;10(10):652-7 - PubMed
  14. Biochemistry. 2008 Jan 22;47(3):1051-60 - PubMed
  15. Int J Oncol. 2004 Apr;24(4):893-900 - PubMed
  16. Transplant Proc. 2003 May;35(3):1109 - PubMed
  17. Life Sci. 1996;58(5):373-95 - PubMed
  18. J Antibiot (Tokyo). 1975 Oct;28(10):721-6 - PubMed
  19. Genes Dev. 2001 Nov 1;15(21):2852-64 - PubMed
  20. Curr Top Med Chem. 2015;15(1):65-72 - PubMed
  21. Cell. 2012 Apr 13;149(2):274-93 - PubMed
  22. BMC Cancer. 2008 Jun 06;8:163 - PubMed
  23. Fam Cancer. 2010 Jun;9(2):125-9 - PubMed
  24. J Cancer Res Clin Oncol. 2009 Jul;135(7):933-41 - PubMed
  25. BMC Bioinformatics. 2004 May 01;5:51 - PubMed
  26. J Antibiot (Tokyo). 1984 Oct;37(10):1231-7 - PubMed
  27. Proc Natl Acad Sci U S A. 2005 May 10;102(19):6665-70 - PubMed
  28. Curr Opin Pharmacol. 2003 Aug;3(4):371-7 - PubMed
  29. Mol Cell. 2003 Aug;12(2):271-80 - PubMed

Publication Types